Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

ICN SELLS 8.6% VOTING STAKE IN HOFFMANN-LAROCHE for an aggregate amount of $209 mil. in a private transaction, the Costa Mesa, Calif.-based firm announced March 24. ICN's holding included 1,380 shares of F. Hoffman-LaRoche voting shares valued at $151,300 each. ICN did not identify the buyer of the Hoffman-LaRoche stake. "In selling our major position in the company," ICN Chairman and CEO Milan Panic said, "we understand and respect Hoffmann-LaRoche's desire to remain in family control for the rest of this century." ICN reported in a September that it had acquired a 6.3% position in Hoffmann-LaRoche for approximately $200 mil. ("The Pink Sheet" Sept. 28, T&G-1). ICN said it "intends to use proceeds from the sale to acquire all or a part of one or more health care companies in order to expand the company's distribution capabilities, supplementing current product lines and adding compatible ones." ICN's profit from the Hoffmann-LaRoche transaction, ICN said, will be reported in the company's soon-to-be-released first quarter sales and earnings statement for the three months ended Feb. 29. The gain from the sale of Roche stock, ICN noted, "will reverse approximately $15.6 mil. of unrealized losses previously recorded" in the company's financial statements for fiscal 1987 (ended Nov. 30, 1987). At that time, ICN reported a $19.4 mil. decline in its portfolio.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts